Dolutegravir/Lamivudine Regimen Effective In Helping Adolescents Living With HIV, Study Shows

The American Journal of Managed Care (2/25) reports a study found that “adolescents living with HIV could have a new form of antiretroviral therapy (ART) available to them after promising results found the 2-drug therapy of dolutegravir/lamivudine was effective after 48 weeks in those who were naive to treatment.” The two-drug therapy “has been used in adults as ART that has been found to be effective in that age group.” Researchers now concluded “that the 2-drug therapy was both safe and effective” for “adolescents aged 12 to 18 years who were living with HIV.” The study was published in the Journal of Acquired Immune Deficiency Syndromes.